Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology

@article{Labrie2015CombinedBO,
  title={Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology},
  author={Fernand Labrie},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2015},
  volume={145},
  pages={144-156}
}
  • F. Labrie
  • Published 31 January 2015
  • Medicine, Biology
  • The Journal of Steroid Biochemistry and Molecular Biology

The importance of targeting intracrinology in prostate cancer management

TLDR
Several drugs have been developed that target intracrinology, some of which are now being used as standard treatment for the so-called castrate-resistant prostate cancer patients, but question is whether those drugs can also be used as the first-line treatment in localized stage PCa cases.

Targeting extra-gonadal androgens in castration-resistant prostate cancer

Role of Hormonal Manipulation in Prostate Cancer Management

TLDR
The present review summarises the chronological evolution of agents used for hormonal manipulation in the management of PCa, highlighting the pros and cons of each and sheds light on the potential future advances in this area.

The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature

  • I. BirdD. Abbott
  • Biology, Medicine
    The Journal of Steroid Biochemistry and Molecular Biology
  • 2016

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database

TLDR
Although there is no FDA indication for BIC use as monotherapy, 44% of patients in this study used BIC alone or as part of CAB followed by monotherapy; further research is necessary to understand the outcomes of BIC utilization in these settings, particularly compared with newer second-generation anti-androgens.

Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer

Roles of renin-angiotensin system in the regulation of prostate cancer bone metastasis: a critical review

  • Medicine, Biology
    annals of urologic oncology
  • 2021
TLDR
This review summarizes and dissects the critical roles of the local RAS in promoting the progression of metastatic prostate cancer, and the development and progression of PCa bone metastasis, thereby providing multiple solutions for the potential therapeutic intervention.

References

SHOWING 1-10 OF 149 REFERENCES

Blockade of testicular and adrenal androgens in prostate cancer treatment

  • F. Labrie
  • Medicine, Biology
    Nature Reviews Urology
  • 2011
TLDR
Combined androgen blockade—medical or surgical castration plus a pure antiandrogen—would be the logical first-line treatment for prostate cancer, although castration or an antiandrogens alone is still chosen in the majority of cases.

New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

TLDR
It is indicated that a combined hormonal therapy which neutralizes all androgenic influences on peripheral tissues is of potential benefit in prostatic cancer and should minimize the development of metastases and androgen-resistant cell clones.

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

TLDR
The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

  • G. AttardA. Reid J. D. de Bono
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC, and data confirm that CRPC commonly remains dependent on ligand-activated AR signaling.

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

  • H. ScherC. Sawyers
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Strategies that are focused on the androgen receptor either directly or indirectly, as single agents or in combination, that are in clinical development that are discussed are discussed.

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.

3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.

TLDR
It is demonstrated that DHEA and A5diol must be metabolized by 3betaHSD to activate AR in these models of CRPC, and suggests that 3 betaHSD may be exploited as a pharmacologic target in the treatment ofCRPC.
...